ArticleHaematologica2020

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.

Akihiro Kitadate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.